Grants Search Results

Based on progress to date, Oren Becher, M.D., AmWINS St. Baldrick's Scholar, was awarded a new grant in 2012 to fund an additional two years of this Scholar award. Brainstem glioma is a rare subtype of brain tumor found mostly in children, which cannot be cured with today's treatments. Dr. Becher’s research suggests that one major obstacle for progress in the treatment of these brain tumors is limited drug delivery due to the blood-brain-barrier, a protective mechanism that prevents the delivery of toxic chemicals into our brains (in this case- the cancer drugs). Dr. Becher is working with genetic models to find new ways to improve the delivery of cancer drugs to these brain tumors.

This grant is named for AmWINS, a wholesale insurance holding company, which has raised more than $1 million for childhood cancer research through the St. Baldrick's Foundation.

Based on progress to date, Dr. Chang was awarded a new grant in 2012 to fund an additional two years of this Scholar award. One subtype of pediatric leukemia that continues to have a poor prognosis is Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ALL). Dr. Chang is researching a unique protein called survivin, in hopes of developing it as a new target for future therapy for Ph+ALL patients.

Based on progress to date, Dr. Lee was awarded a new grant in 2012 to fund an additional two years of this Scholar award. Natural killer cells (NK cells), one of the white blood cells of our immune system, have the ability to kill several types of cancers in children, including AML, neuroblastoma, osteosarcoma, and Ewing's sarcoma. Dr. Lee's research involves more effective ways to use NK cells to fight childhood cancers.

Acute myeloid leukemia (AML) is a potentially deadly form of childhood leukemia. Dr. Vaiselbuh is studying how AML cancer cells resist chemotherapy with the goal of finding a new strategy for treatment of childhood myeloid leukemia.

Based on progress to date, Dr. Volchenboum was awarded a new grant in 2012 to fund an additional two years of this Scholar award. Neuroblastoma strikes in many forms, some requiring little or no therapy, others deadly despite very aggressive treatment. Current tests that differentiate among these types can take weeks. Dr. Volchenboum is developing software to make real-time diagnosis possible, allowing therapy to be better tailored to the specific child. Once validated, these new technologies can be extended to other pediatric cancers.

Based on progress to date, Dr. Yustein was awarded a new grant in 2012 to fund an additional two years of this Scholar award. Many human malignancies have abnormal expression or activity of a protein called c-Myc, leading to genetic changes critical to tumor survival and growth. Dr. Yustein's research is on the role c-Myc plays in Ewings sarcomas, osteosarcomas and rhabdomyosarcomas.

Cancer is a disease caused by mistakes in the DNA of tumor cells. Identifying all these mistakes in a single type of cancer has been slow, but understanding them will revolutionize the way cancer is diagnosed and treated. This project makes use of exciting new developments in "sequencing technology" to identify all the DNA mistakes in neuroblastoma. This is the very first such effort ever undertaken for a pediatric cancer, and leverages the support and expertise of investigators at Children's Hospital of Philadelphia, the Children's Oncology Group and Johns Hopkins University.

Pleuropulmonary blastoma (PPB) is a rare but biologically important lung cancer of young children. Recently identified inherited genetic mutations predispose children to developing PPB, leukemia and other childhood tumors arising in the muscle, brain, ovary and kidneys. To understand how these tumors form and progress, this research uses models based upon genetic discoveries in families with hereditary PPB, by identifying the cellular events responsible for PPB initiation and progression. This is an essential step toward developing ways to detect, treat and improve outcomes for children with PPB and the related tumors associated with this inherited cancer predisposition syndrome.

This new doctor is supported for training to specialize in pediatric oncology research, funded for 2 years or more.

This new doctor is supported for training to specialize in pediatric oncology research, funded for 2 years or more.

This new doctor is supported for training to specialize in pediatric oncology research, funded for 2 years or more.

This new doctor is supported for training to specialize in pediatric oncology research, funded for 2 years or more.

This new doctor is supported for training to specialize in pediatric oncology research, funded for 2 years or more.

This grant helps keep this young professional focused on childhood cancer by supporting exciting research, funded for 3 years or more.

This grant funded a cutting-edge research project to find new and better cures for childhood cancer.

This grant funds a cutting-edge research project to find new and better cures for childhood cancer.

This grant funds a cutting-edge research project to find new and better cures for childhood cancer.

This grant funded a cutting-edge research project to find new and better cures for childhood cancer.

This grant funds a cutting-edge research project to find new and better cures for childhood cancer.

This grant funds a cutting-edge research project to find new and better cures for childhood cancer.